Biogen (BIIB) said Tuesday that it has initiated dosing in the phase 3 Transcend study of felzartamab to treat adult kidney transplant recipients diagnosed with late antibody-mediated rejection, or late AMR.

The biotech company said the study, which will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo, will enroll approximately 120 kidney transplant recipients with late AMR.

The primary endpoint of study is the percentage of participants who achieve resolution by biopsy of AMR at 6 months.

Price: 149.33, Change: -1.38, Percent Change: -0.92